

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-45 (Canceled)

46. (Currently amended) A pharmaceutical composition comprising a ~~phosphate acceptor compound (PAC) which is a phosvitin or fragment thereof~~ protein or peptide which is at least partially 10% dephosphorylated and a pharmaceutically-acceptable carrier, wherein the pharmaceutical composition is not an aqueous solution or a lyophilized material.

47-48 (Canceled)

49. (Currently amended) The composition of Claim ~~48~~ 46 wherein the phosvitin is chicken phosvitin.

50. (Previously presented) The composition of Claim 280 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

51. (Original) The composition of Claim 50 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

52 (Original) The composition of Claim 51 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

53. (Original) The composition of Claim 52 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

54-80 (Canceled)

81. (Previously presented) A kit for contacting a cell, a tissue or an organ that has been removed from an animal ~~with an extracellular phosphate acceptor compound (EPAC) or a combination of EPACs~~, the kit comprising:

(a) ~~one or a combination of the following:~~

a container holding ~~an EPAC~~ a phosvitin or fragment thereof which is at least 10% dephosphorylated;

a container holding a combination of EPACs; or  
\_\_\_\_\_ a plurality of containers each holding an EPAC, wherein each of the plurality of EPACs may be the same as, or different than, the other EPAC(s); and

(b) instructions describing how to use the kit to contact a cell, tissue or organ with the phosvitin or fragment thereof EPAC(s) in the kit.

82-185 (Canceled)

186. (Currently amended) A pharmaceutical composition which is formulated for topical administration to an animal and which is not an aqueous solution, the composition comprising a phosvitin or fragment thereof ~~phosphate acceptor compound (PAC)~~ which is a protein or peptide which is at least 10% partially dephosphorylated and a pharmaceutically-acceptable carrier.

187-193 (Canceled)

194. (Currently amended) The composition of Claim ~~193~~ 186 wherein the phosvitin is chicken phosvitin.

195. (Currently amended) The composition of Claim ~~193~~ 186 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

196. (Previously presented) The composition of Claim 195 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

197. (Previously presented) The composition of Claim 196 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

198. (Previously presented) The composition of Claim 197 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

199. (Previously presented) The composition of Claim 198 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

200-216 (Canceled)

Appl. No. 10/723,247  
Amdt. dated November 20, 2007  
Reply to Office Action mailed May 23, 2007

217. (Currently amended) The pharmaceutical composition of Claim ~~186~~ any one of Claims 186, 195-199 or 288 which is formulated for topical administration to the skin of an animal.

218. (Currently amended) The pharmaceutical composition of Claim ~~186~~ any one of Claims 186, 195-199 or 288 which is drops, a spray, an aerosol or an inhalant.

219. (Currently amended) The pharmaceutical composition of Claim ~~186~~ any one of Claims 186, 195-199 or 288 which is a powder or a foam.

220. (Currently amended) The pharmaceutical composition of Claim ~~186~~ any one of Claims 186, 195-199 or 288 which is a lotion, a gel, a cream, an ointment or a paste.

221-245 (Canceled)

246. (Previously presented) The pharmaceutical composition of Claim 220 which is an ointment or a cream.

247-271 (Canceled)

272. (Currently amended) A pharmaceutical composition comprising a phosvitin or fragment thereof which is at least 10% dephosphorylated and phosphate acceptor compound (PAC) which has a targeting molecule attached to it and a pharmaceutically-acceptable carrier.

273. (Currently amended) The composition of Claim 272 ~~271~~ wherein the composition is formulated for topical administration to an animal ~~PAC is an extracellular phosphate acceptor compound (EPAC).~~

273-279 (Canceled)

280. (Currently amended) The composition of Claim ~~48~~ 46 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

281. (New) The composition of Claim 53 wherein the phosvitin or fragment thereof is unphosphorylated.

282. (New) The composition of Claim 49 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

283. (New) The composition of Claim 282 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

284. (New) The composition of Claim 283 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

285. (New) The composition of Claim 284 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

286. (New) The composition of Claim 285 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

287. (New) The composition of Claim 286 wherein the phosvitin or fragment thereof is unphosphorylated.

288. (New) The composition of Claim 199 wherein the phosvitin or fragment thereof is unphosphorylated.

289. (New) The composition of Claim 194 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

290. (New) The composition of Claim 289 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

291. (New) The composition of Claim 290 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

292. (New) The composition of Claim 291 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

293. (New) The composition of Claim 292 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

294. (New) The composition of Claim 293 wherein the phosvitin or fragment thereof is unphosphorylated.

295. (New) The pharmaceutical composition of any one of Claims 194 or 289-294 which is formulated for topical administration to the skin of an animal.

Appl. No. 10/723,247

Amdt. dated November 20, 2007

Reply to Office Action mailed May 23, 2007

296. (New) The pharmaceutical composition of any one of Claims 194 or 289-294 which is drops, a spray, an aerosol or an inhalant.

297. (New) The pharmaceutical composition of any one of Claims 194 or 289-294 which is a powder or a foam.

298. (New) The pharmaceutical composition of any one of Claims 194 or 289-294 which is a lotion, a gel, a cream, an ointment or a paste.

299. (New) The pharmaceutical composition of Claim 298 which is an ointment or a cream.